Based on the Nkarta Inc stock forecast from 2 analysts, the average analyst target price for Nkarta Inc is USD 16.00 over the next 12 months. Nkarta Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Nkarta Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Nkarta Inc’s stock price was USD 1.57. Nkarta Inc’s stock price has changed by -17.80% over the past week, -14.67% over the past month and -80.52% over the last year.
No recent analyst target price found for Nkarta Inc
No recent average analyst rating found for Nkarta Inc
Company Overview Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Read Less
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 ...Read More
Frequently Asked Questions About Nkarta Inc (NKTX) Stock
Based on ratings from 2 analysts Nkarta Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on NKTX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for NKTX is USD 16.00 over the next 12 months. The maximum analyst target price is USD 18 while the minimum anlayst target price is USD 14.
Unfortunately we do not have enough data on NKTX's stock to indicate if its overvalued.
The last closing price of NKTX's stock was USD 1.57.
The most recent market capitalization for NKTX is USD 0.13B.
Based on targets from 2 analysts, the average taret price for NKTX is projected at USD 16.00 over the next 12 months.
This means that NKTX's stock price may go up by +919.11% over the next 12 months.
We can't find any ETFs which contains Nkarta Inc's stock.
As per our most recent records Nkarta Inc has 159 Employees.
Nkarta Inc's registered address is 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Nkarta Inc's website at https://www.nkartatx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Nkarta Inc (NKTX) Stock
Based on ratings from 2 analysts Nkarta Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on NKTX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for NKTX is USD 16.00 over the next 12 months. The maximum analyst target price is USD 18 while the minimum anlayst target price is USD 14.
Unfortunately we do not have enough data on NKTX's stock to indicate if its overvalued.
The last closing price of NKTX's stock was USD 1.57.
The most recent market capitalization for NKTX is USD 0.13B.
Based on targets from 2 analysts, the average taret price for NKTX is projected at USD 16.00 over the next 12 months.
This means that NKTX's stock price may go up by +919.11% over the next 12 months.
We can't find any ETFs which contains Nkarta Inc's stock.
As per our most recent records Nkarta Inc has 159 Employees.
Nkarta Inc's registered address is 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Nkarta Inc's website at https://www.nkartatx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NKTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
